Kishan Patel

heme/onc fellow @mskcancercenter | alum @brighammedres, @yalemed, @brownuniversity

[JAMA @JAMA_current]

📝 JAMA #Review: #ClassicHodgkinLymphoma is usually treated with chemotherapy, with radiotherapy added for some early-stage disease and anti–programmed cell death 1 immunotherapy or brentuximab vedotin used in select higher-risk settings.

https://t.co/R4Hik2Hi1O

[Kishan Patel @KishKPatel]

@MassimoDiMaio75 something to look into!

[Kishan Patel @KishKPatel]

excited to see this out today - looking at deficiencies in PRO/QOL reporting in pivotal heme malignancy trials!

[JAMA Network Open @JAMANetworkOpen]

A systematic review of phase III clinical trials of hematologic cancers found that there is widespread collection of patient-reported outcomes (PROs), but limited reporting of PRO data in associated primary trial publications, suggesting publication bias. https://t.co/Mb6vn1cBTA

[Kishan Patel @KishKPatel]

@allisonoconn this past cycle, applications were released to programs on July 19th - I asked letter writers to submit by end of June, to give a little buffer time (and account for any processing time)!

[Jonah Rubin MD, FCCP @JonahRubinMD]

As we naturally compare specialties in the JAMA graph, it's important to also look what happens when you draw the axes out fully ⤵️

The overall burnout is the problem.

#MedTwitter @jbcarmody

[Dr. Glaucomflecken @DGlaucomflecken]

The residents have unionized

[Kishan Patel @KishKPatel]

CONGRATS EVERYONE

[Jose Figueroa, MD, MPH @joefigs2]

Congrats to all medical students who matched today!

Especially excited to welcome the incredible new incoming @BrighamMedRes intern class! @BrighamWomens

27% are from URM backgrounds! @Brigham_DI

[Kishan Patel @KishKPatel]

our study out in this week's issue of @BloodJournal - CPX-351 not cost-effective compared to traditional 7+3 in AML

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Our latest paper in @BloodJournal Cost-effectiveness of liposomal cytarabine/daunorubicin in patients wi... https://t.co/950Y6QoxQr

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

“I will never be ok again.” 🖤 https://t.co/yzKZqcKBs9

[Kishan Patel @KishKPatel]

@chadinabhan unsurprising for the US, but interesting that this also applies for the european countries, despite their use of CEA in approval decisions

[Kishan Patel @KishKPatel]

new study re: value of selinexor in r/r myeloma - high cost, significant toxicity and marginal clinical benefit. https://t.co/LTw0HYkTk0 @smith__giri

[Max Jordan Nguemeni @MaxJordan_N]

More grad pics! Here is the incoming @BrighamMedRes crew coming from @YaleMed. Didn’t get the mask off memo here, the university’s emails about masking at graduation were so stern lol
Not pictured are Patrick Liu (Med Peds) & Mary Sun (IM prelim-Derm). Nice lil Yale cocoon yeah?

[Aria @xANMD]

Using data from the #ENIGMA RCT studies, we show that N2O anesthesia did not increase the risk of postoperative complications or length of hospital stay for neurosurgical patients - https://t.co/tcmAYDFwE4
@KishKPatel @GenevaNeurosurg @YNeurosurgery @UCNeurosurgery
#Neurosurgery

[Kishan Patel @KishKPatel]

@_NelsonUgwu @harvardmed @BIDMC_Medicine 🔥🔥🔥

[Max Jordan Nguemeni @MaxJordan_N]

During interview szn I avoided all online forums. I kept in touch w/ 3 applicants regularly: 2 #BMIM, @dereckwpaul & one who’s not on here (I was afraid of being one of too few Black men in whichever program) plus my @yalemed friend @KishKPatel. Now we all gonna be co-interns 🙌🏾

[Kishan Patel @KishKPatel]

@MaxJordan_N @dereckwpaul @YaleMed @BrighamMedRes @valstonemd can't wait!!

[Kishan Patel @KishKPatel]

thanks Dr. Malinis!

[maricar malinis @maricar_malinis]

Congratulations to @YaleMed student ⭐️@KishKPatel for his accepted @ATCMeeting 2021 abstract! #oralpresentation #proudmentor @YaleIMed @YaleTransplant @yaletxpneph @YaleIDFellows @YNHH

[Matt Meizlish @MattMeiz]

Access to health care shouldn’t depend on immigration status. CT providers say it’s time to expand Medicaid eligibility to undocumented immigrants https://t.co/xyzhx03LJJ

@SenatorMooreCT @RepAbercrombie @MattLesser will you hold a public hearing for SB956? #HUSKY4Immigrants

[Kishan Patel @KishKPatel]

new study out in @BloodAdvances, looking at aza/ven in unfit AML. @sfhYALE @Dr_AmerZeidan

[Blood Advances @BloodAdvances]

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia https://t.co/urDMWasJST

[Pramesh CS @cspramesh]

Great work by Connor Wells & Shubham Sharma @QueensUHealth asking two important #GlobalHealth questions
1. Is there a #publicationbias against papers from #LMICs?
2. Do oncology RCTs match the global disease burden?
Confirms something we always knew
What we did was this...